Track market-moving stories before they get noisy

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi.

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,587,119.60. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Trading Down 1.5% UTHR stock opened at $533.12 on Friday. The stock’s 50 day simple moving average is $513.64 and its 200 day simple moving average is $540.40. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35. The stock has a market capitalization of $22.87 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 3.81 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $6.41 EPS. On average, research analysts predict that United Therapeutics Corporation will post 26.40 earnings per share for the current year.

Analyst Ratings Changes Several equities research analysts recently commented on the company. The Goldman Sachs Group reaffirmed a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a research report on Thursday. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research note on Thursday, October 1st. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Finally, Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $642.69. View Our Latest Stock Analysis on United Therapeutics

More United Therapeutics News Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares. Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels. Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing Institutional Investors Weigh In On United Therapeutics A number of hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its holdings in shares of United Therapeutics by 31.5% during the 3rd quarter. IFP Advisors Inc now owns 2,030 shares of the biotechnology company’s stock valued at $1,100,000 after buying an additional 486 shares during the period. Frank Rimerman Advisors LLC grew its holdings in shares of United Therapeutics by 11.2% in the third quarter. Frank Rimerman Advisors LLC now owns 426 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 43 shares during the period. New England Research & Management Inc. grew its holdings in shares of United Therapeutics by 110.1% in the third quarter. New England Research & Management Inc. now owns 3,530 shares of the biotechnology company’s stock worth $1,913,000 after acquiring an additional 1,850 shares during the period. TD Waterhouse Canada Inc. grew its holdings in shares of United Therapeutics by 6.0% in the third quarter. TD Waterhouse Canada Inc. now owns 1,302 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 74 shares during the period. Finally, Pension & Wealth Management Advisors Inc. purchased a new stake in United Therapeutics during the third quarter valued at $108,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile (Get Free Report)

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

Featured Articles Five stocks we like better than United Therapeutics Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

First Citizens Bank & Trust Co. trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 59.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,522 shares of the biotechnology company’s stock after selling 2,241 shares during the period. First Citizens Bank & Trust Co.’s holdings in United Therapeutics were worth $825,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Callan Family Office LLC bought a new position in United Therapeutics during the second quarter valued at approximately $1,217,000. Andra AP fonden grew its position in United Therapeutics by 33.5% in the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after acquiring an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in United Therapeutics in the second quarter worth approximately $3,359,000. Partners Capital Investment Group LLP acquired a new position in shares of United Therapeutics during the 2nd quarter worth $1,691,000. Finally, Hsbc Holdings PLC increased its stake in shares of United Therapeutics by 6.6% during the 2nd quarter. Hsbc Holdings PLC now owns 127,125 shares of the biotechnology company’s stock worth $68,899,000 after purchasing an additional 7,890 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.5% Shares of United Therapeutics stock opened at $533.12 on Friday. The stock has a market capitalization of $22.87 billion, a P/E ratio of 19.07, a PEG ratio of 3.87 and a beta of 0.49. The stock has a 50 day moving average price of $513.64 and a two-hundred day moving average price of $540.40. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the company posted $6.41 earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.40 earnings per share for the current year. More United Therapeutics News Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares. Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels. Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing Analyst Ratings Changes A number of research analysts have recently weighed in on the stock. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Morgan Stanley increased their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $642.69.

View Our Latest Analysis on United Therapeutics

Insiders Place Their Bets In related news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $539.99, for a total value of $5,129,905.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $175,195,975.57. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $24,587,119.60. This trade represents a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 392,028 shares of company stock valued at $202,884,996 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Profile (Free Report)

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

See Also Five stocks we like better than United Therapeutics Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure helps cut through all the noise.

The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Halozyme Therapeutics?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Halozyme Therapeutics (HALO - Free Report) holds a #1 (Strong Buy) at the moment and its Most Accurate Estimate comes in at $2.34 a share 19 days away from its upcoming earnings release on November 2, 2026.

HALO has an Earnings ESP figure of +2.78%, which, as explained above, is calculated by taking the percentage difference between the $2.34 Most Accurate Estimate and the Zacks Consensus Estimate of $2.28. Halozyme Therapeutics is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

HALO is just one of a large group of Medical stocks with a positive ESP figure. United Therapeutics (UTHR - Free Report) is another qualifying stock you may want to consider.

Slated to report earnings on November 4, 2026, United Therapeutics holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $6.35 a share 21 days from its next quarterly update.

The Zacks Consensus Estimate for United Therapeutics is $6.26, and when you take the percentage difference between that number and its Most Accurate Estimate, you get the Earnings ESP figure of +1.52%.

HALO and UTHR's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $548.95, for a total value of $5,215,025.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $178,102,984.85. The trade was a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Performance Shares of NASDAQ UTHR opened at $549.16 on Friday. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The firm has a market capitalization of $23.55 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 2.73 and a beta of 0.49. The stock’s 50-day simple moving average is $512.00 and its 200-day simple moving average is $540.00.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the business posted $6.41 EPS. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.

Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in United Therapeutics during the second quarter valued at $2,868,735,000. Janus Henderson Group PLC boosted its position in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after acquiring an additional 70,829 shares during the period. Jupiter Topco LLC acquired a new stake in United Therapeutics during the 2nd quarter worth about $450,140,000. Swedbank AB boosted its position in United Therapeutics by 0.7% during the 1st quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after acquiring an additional 2,350 shares during the period. Finally, Pictet Asset Management Holding SA grew its stake in United Therapeutics by 0.8% during the 1st quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock valued at $183,306,000 after acquiring an additional 2,383 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock. Analysts Set New Price Targets A number of research analysts have commented on the stock. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a research note on Thursday. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, The Goldman Sachs Group initiated coverage on United Therapeutics in a research note on Thursday, September 24th. They set a “sell” rating and a $321.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $627.31.

Read Our Latest Research Report on UTHR

(Get Free Report)

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

Read More Five stocks we like better than United Therapeutics 3 Unique ETFs With Strong Momentum for the End of the Year 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone? Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways UTHR won a ruling that Liquidia infringes two patent claims covering inhaled treprostinil use in PH-ILD.Yutrepia may lose its PH-ILD label or face market removal, subject to the final judgment and FDA action.UTHR could benefit from reduced competition and plans to seek monetary damages for past infringement. United Therapeutics (UTHR - Free Report) announced that it has received a favorable ruling in its patent litigation against Liquidia Technologies (LQDA - Free Report) concerning the latter’s lead product, Yutrepia, a dry-powder inhaled formulation of treprostinil. UTHR shares rose nearly 13% following the announcement.

United Therapeutics and Liquidia Technologies compete directly in the market for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH) market through their inhaled treprostinil products, with UTHR offering Tyvaso and Tyvaso DPI and LQDA competing with its newly launched dry-powder formulation, Yutrepia.

United Therapeutics has been marketing Tyvaso for PAH since 2009 and expanded its label to PH-ILD in 2021. The company subsequently received FDA approval for Tyvaso DPI in 2022 for PAH and PH-ILD. Meanwhile, the FDA approved Yutrepia in May 2025 for the treatment of PAH and PH-ILD and began commercialization in June 2025.

The U.S. District Court for the District of Delaware ruled that Liquidia infringes claims one and 14 of United Therapeutics’ ’327 patent. The patent covers the use of inhaled treprostinil at specific doses to improve exercise capacity in patients with PH-ILD.

The court rejected Liquidia’s arguments that these two claims were invalid. This ruling strengthens United Therapeutics’ position in protecting its PH-ILD franchise.

Year to date, shares of United Therapeutics have risen 11.2% against the industry’s 4.4% decline.

Image Source: Zacks Investment Research

Potential Impact on LQDA’s YutrepiaThe ruling could create significant challenges for Liquidia’s Yutrepia. United Therapeutics believes the court could order the FDA to withdraw Yutrepia’s approval under the relevant patent law provisions. If the court issues such an order, Yutrepia could be removed from the U.S. market until Liquidia obtains FDA approval for a label that excludes the PH-ILD indication.

However, the outcome is not yet certain. The court has given both companies one week to submit an agreed form of final judgment. If they cannot agree on the appropriate remedies, the court will decide the matter.

UTHR Could Benefit From Reduced CompetitionA restriction on Yutrepia's PH-ILD use could benefit United Therapeutics, as the company already markets two inhaled treprostinil products for this indication, nebulized Tyvaso and the Tyvaso DPI formulation. These Tyvaso products are the key drivers of the company’s top line. The company could therefore see less competitive pressure in the PH-ILD market if Yutrepia loses its PH-ILD indication or faces broader market restrictions.

United Therapeutics has stated that it is prepared to help patients transition to Tyvaso products if PH-ILD is removed from the Yutrepia label. This could help the company retain patients who currently use Yutrepia.

The patent dispute could also have a financial benefit beyond future competition. United Therapeutics intends to seek monetary damages for past infringement.

The potential damages could include a royalty on past Yutrepia sales. However, the ultimate commercial and financial impact will depend on the final judgment, any FDA action and the outcome of Liquidia’s potential appeals.

UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) and AC Immune (ACIU - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 24 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 73 cents. PGEN shares have gained 104.8% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents per share. ACIU shares have lost 16.6% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Mizuho analyst Nick Setyan upgraded BJ’s Restaurants Inc (NASDAQ:BJRI) from Neutral to Outperform and raised the price target from $74 to $76. BJ’s Restaurants closed at $57.29 on Wednesday. See how other analysts view this stock. BTIG analyst Julian Harrison upgraded United Therapeutics Corporation (NASDAQ:UTHR) from Neutral to Buy and announced a $728 price target. United Therapeutics shares closed at $541.89 on Wednesday. See how other analysts view this stock. Goldman Sachs analyst Neil Mehta upgraded Occidental Petroleum Corporation (NYSE:OXY) from Neutral to Buy and boosted the price target from $63 to $69. Occidental Petroleum closed at $55.32 on Wednesday. See how other analysts view this stock. Wells Fargo analyst Sam Margolin upgraded BP p.l.c. (NYSE:BP) from Equal-Weight to Overweight and raised the price target from $48 to $57. BP shares closed at $43.99 on Wednesday. See how other analysts view this stock. Argus Research analyst Jasper Hellweg upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from Hold to Buy and announced a price target of $850. Regeneron Pharmaceuticals closed at $758.27 on Wednesday. See how other analysts view this stock. Considering buying UTHR stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) are rising in Thursday morning trading following a federal court victory in its patent litigation against competitor Liquidia Corp.

Here’s what investors need to know.

United Therapeutics stock is moving in positive territory. What’s pushing UTHR stock higher? Federal Court Patent Ruling Against LiquidiaThe company announced late Wednesday that the U.S. District Court for the District of Delaware ruled in favor of United Therapeutics in its patent infringement lawsuit against Liquidia.

The court determined that Liquidia induces infringement of claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327, which covers the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court further concluded that Liquidia failed to prove the patent claims were invalid.

As a result of the ruling, United Therapeutics stated it is seeking a court order instructing the U.S. Food and Drug Administration to withdraw its approval of Liquidia’s New Drug Application for Yutrepia, which could force the competing drug off the U.S. market until its label omits the PH-ILD indication. The company also intends to pursue monetary damages and royalties on past Yutrepia sales.

Management Reaction and BTIG UpgradeThe court set a one-week deadline for both parties to submit an agreed-upon form of final judgment. The decision fortifies United Therapeutics’ market leadership with its approved Tyvaso and Tyvaso DPI products.

“We are pleased with the Court’s decision, which reinforces our significant research and commitment to bring innovative therapies to the patients we serve,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “Our immediate priority is ensuring that no patient goes without the therapy they need, and we are ready to support a seamless transition to Tyvaso or Tyvaso DPI should PH-ILD be removed from the Yutrepia label.”

On Thursday morning, BTIG analyst Julian Harrison upgraded United Therapeutics from Neutral to Buy, setting a street-high price target of $728 on the stock.

UTHR Stock Rises Thursday MorningUTHR Price Action: United Therapeutics shares were up 1.44% at $549.69 during premarket trading on Thursday, according to Benzinga Pro data.

Read Next

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.

3 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

These 3 Stocks Lowered Their Share Counts Drastically in Q1United Therapeutics NASDAQ: UTHR outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share repurchases.

Founder, Chairperson and Chief Executive Officer Martine Rothblatt said the company is positioned for what she characterized as an “exponential growth trajectory,” driven largely by therapies for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), interstitial lung disease (ILD) and pulmonary hypertension (PH).

Get United Therapeutics alerts:

Pulmonary fibrosis expansion The Top 3 Stock Picks at the World’s Greatest Hedge FundRothblatt said the FDA has accepted United Therapeutics’ new drug application for nebulized Tyvaso in IPF, with a PDUFA action date expected early next year. The company also plans to pursue the use of Tyvaso DPI, an approved dry-powder inhalation product, in IPF and PPF.

She said the company is developing CoughLess Trezmi, a soft-mist inhaled therapy, for ILD, IPF and PPF. United Therapeutics expects to submit an NDA for that product before year-end and anticipates a launch next year, according to Rothblatt.

Liquidia: Court victory the awakening of an industry giant?Another pipeline candidate, Once Daily Ralpi, is being developed for IPF, PPF and ILD. Rothblatt said the molecule has once-daily dosing potential and, in the company’s view, has stronger anti-fibrotic activity than treprostinil.

Rothblatt also discussed the company’s IPF development strategy for nebulized Tyvaso. She said United Therapeutics used secondary endpoints from its prior INCREASE study in PH-ILD to support its request to move into a Phase III IPF study. The FDA required two adequate and well-controlled Phase III trials in IPF, she said.

The company subsequently completed the TETON-1 and TETON-2 studies, which Rothblatt said showed an improvement in forced vital capacity. She said the results supported the company’s expectation that Tyvaso could provide a meaningful clinical benefit for pulmonary fibrosis patients. United Therapeutics has doubled its sales force in preparation for a potential IPF launch and plans to launch in Europe as well, she said.

For PPF, Rothblatt said the FDA allowed the company to conduct a single study. That trial is fully enrolled, with results expected to be unblinded next year.

Ralinepag and capital allocation United Therapeutics has submitted ralinepag, a once-daily oral therapy for pulmonary hypertension, to the FDA. Rothblatt said the agency assigned a PDUFA date of June 24 next year. She described ralinepag as the only drug tested in pulmonary hypertension that demonstrated clinical improvement in patients, in addition to slowing disease progression.

The company is also developing a triple-combination version of ralinepag that would include a PDE5 inhibitor and an endothelin receptor antagonist, or ERA, in a single pill. Rothblatt said the program is intended to reduce patients’ pill burden.

Other development programs include TRESMI for COPD-associated pulmonary hypertension, an indication Rothblatt said affects about 600,000 U.S. patients and currently has no approved therapies. The company is also developing ILO Tra, a rescue inhaler for pulmonary hypertension that combines two prostacyclin-type molecules.

Chief Financial Officer James Edgemond said capital allocation remains a major focus as the company invests in its development programs. He said United Therapeutics is actively repurchasing shares under a $2 billion authorization approved by the board earlier this year.

“We think with this explosive growth on the horizon and where we see the value of the stock today is one of the best uses of capital that we are pursuing right now,” Edgemond said.

Organ manufacturing plans Rothblatt also detailed United Therapeutics’ xenotransplantation programs, which use genetically modified pig organs for human transplantation. The company is conducting a registration trial of its xenokidney program, with four patients already transplanted and two additional procedures planned this year, she said.

After the sixth patient reaches three months following transplantation, United Therapeutics expects to present data to the FDA to seek authorization to continue the trial. Rothblatt said the company expects the trial to enroll 30 patients in total by 2028 and aims for potential commercial availability no later than 2030.

The company has built three commercial xenograft production facilities in Virginia, Rochester, Minnesota, and Houston. Edgemond said United Therapeutics adjusted its manufacturing plans over time to reduce upfront capital requirements and better align future facility investments with commercial demand.

United Therapeutics is also pursuing clinical programs involving xenotransplanted hearts and its UThymoKidney and UHeart concepts. Rothblatt said those programs incorporate thymus tissue intended to train a recipient’s immune system to recognize the transplanted pig organ, potentially reducing or eliminating the need for chronic immunosuppression.

Finally, Rothblatt highlighted the company’s Computational Laboratory for In Silico Molecular Biology, or CLIMB, which she said was developed to create a detailed digital model of the lung for evaluating potential treatments in pulmonary hypertension and pulmonary fibrosis. She said the company has used the model in assessing internal drug candidates and is receiving interest from pharmaceutical companies seeking to test their molecules through the platform.

About United Therapeutics (NASDAQ:UTHR)United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in United Therapeutics Right Now?Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

SummaryUnited Therapeutics has declined ~12% since my last review, reducing its market cap to ~$21.1 billion.My previous rating was "buy" based on a compelling 2026 Tyvaso franchise plus upcoming catalysts, reflecting valuation and risk considerations.UTHR's current "buy" investment thesis centers on upcoming PDUFA dates and other catalysts that could drive future growth and re-rate the stock.The article's focus is on reassessing UTHR's valuation and strategic positioning following recent share price weakness despite significant pipeline developments. bob_bosewell/iStock via Getty Images

This is my fifth look at United Therapeutics Corporation (UTHR) following my fourth, 07/06/2026's "United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy". In Compelling Buy, I rated United

7.79K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of UTHR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may buy additional shares over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking. 

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $504.12, for a total transaction of $4,789,140.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $163,558,205.16. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

UTHR opened at $498.48 on Thursday. The stock has a market capitalization of $21.38 billion, a price-to-earnings ratio of 17.83, a PEG ratio of 2.51 and a beta of 0.56. The firm has a 50 day moving average price of $517.63 and a 200-day moving average price of $540.68. United Therapeutics Corporation has a twelve month low of $397.97 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the company posted $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Wall Street Analyst Weigh In A number of research firms have recently issued reports on UTHR. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $646.00. Read Our Latest Research Report on UTHR

Institutional Trading of United Therapeutics Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of United Therapeutics in the second quarter worth $2,868,735,000. Jupiter Topco LLC purchased a new position in United Therapeutics during the second quarter valued at $450,140,000. Norges Bank purchased a new position in United Therapeutics during the fourth quarter valued at $293,418,000. Bank of New York Mellon Corp bought a new stake in United Therapeutics in the 2nd quarter valued at $159,522,000. Finally, Caisse de depot et placement du Quebec bought a new stake in United Therapeutics in the 2nd quarter valued at $154,304,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile (Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

Read More Five stocks we like better than United Therapeutics 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Jackson’s Record Quarter Powers the Bull Case Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $502.35, for a total value of $4,772,325.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $162,983,941.05. This represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Down 1.3% Shares of NASDAQ:UTHR opened at $497.11 on Friday. The stock has a market capitalization of $21.32 billion, a P/E ratio of 17.79, a P/E/G ratio of 2.48 and a beta of 0.56. United Therapeutics Corporation has a 1-year low of $396.12 and a 1-year high of $609.35. The business has a 50-day moving average price of $520.91 and a two-hundred day moving average price of $540.30.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the company posted $6.41 EPS. The company’s revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics Several institutional investors and hedge funds have recently modified their holdings of the business. Toth Financial Advisory Corp raised its holdings in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $30,000. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In UTHR has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Check Out Our Latest Stock Report on UTHR

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

Featured Articles Five stocks we like better than United Therapeutics Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy? Optical Cable Corporation Is Starting to Get the Market’s Attention Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers Is Nike’s Index Demotion a Warning or a Buying Opportunity?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To complete the utilization, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase the company's common stock, for approximately $477.6 million. T.

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso® (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency's review to be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication. “.

Freestone Grove Partners LP bought a new position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,207 shares of the biotechnology company’s stock, valued at approximately $654,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the period. Jump Financial LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $277,000. Cerity Partners LLC grew its holdings in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia grew its holdings in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities research analysts recently issued reports on the company. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Check Out Our Latest Stock Analysis on UTHR United Therapeutics Price Performance Shares of NASDAQ UTHR opened at $515.46 on Monday. The business has a 50-day moving average of $530.46 and a 200-day moving average of $539.16. The stock has a market capitalization of $22.11 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $303.08 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the company posted $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Buying and Selling In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. The trade was a 19.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 404,575 shares of company stock valued at $216,652,640. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile (Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories Five stocks we like better than United Therapeutics Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-9 in Barcelona. The presentations include late-breaking a.

Key Takeaways United Therapeutics' ralinepag NDA was accepted by the FDA, with a decision expected on June 24, 2027.Ralinepag cut clinical worsening risk by 55% versus placebo and improved key secondary endpoints.The once-daily oral therapy also improved six-minute walk distance and NT-proBNP levels in PAH patients. United Therapeutics (UTHR - Free Report) announced that the FDA has accepted the new drug application (NDA) seeking approval for its investigational drug, ralinepag, a once-daily oral prostacyclin receptor agonist for treating pulmonary arterial hypertension (PAH). A decision from the regulatory body is expected on June 24, 2027.

PAH is a rare and life-threatening condition marked by high blood pressure in the lung arteries, which can strain the heart and eventually cause heart failure. It affects about 500,000 people worldwide, including 50,000 in the United States, while many cases remain undiagnosed or untreated.

Year to date, shares of United Therapeutics have risen 8.3% compared with the industry’s 2.3% growth.

Image Source: Zacks Investment Research

Ralinepag NDA Backed by UTHR’s Positive Phase III DataUnited Therapeutics submitted the NDA for oral ralinepag in PAH indications to the FDA in June. The filing was based on positive data from the phase III ADVANCE OUTCOMES study. The study met its primary endpoints by demonstrating that treatment with ralinepag reduced the risk of clinical worsening by 55% versus placebo and showed durable efficacy in delaying disease progression in patients with PAH. Statistically significant improvements were observed across key secondary endpoints such as six-minute walk distance and changes in N-terminal pro-B-type natriuretic peptide levels.

If approved, ralinepag would become the first and only once-daily oral prostacyclin approved by the FDA for PAH. UTHR’s convenient dosing could provide an attractive option for patients while helping the company address competitive pressures facing its existing PAH portfolio.

UTHR’s Established PAH Franchise Provides Strong FoundationUnited Therapeutics has an established presence in the PAH market, with four marketed therapies: Tyvaso, Orenitram, Adcirca and Remodulin. Tyvaso products are among the key contributors to the company’s revenues. The company markets Tyvaso in two formulations, Tyvaso DPI and nebulized Tyvaso. Both are approved for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company is advancing Tresmi, an investigational inhaled treprostinil solution delivered via a soft mist inhaler for the treatment of PAH and PH-ILD. The therapy is designed to reduce coughing by up to 90% compared with Tyvaso DPI. UTHR plans to submit regulatory applications for PAH and PH-ILD in 2026, with a commercial launch in 2027, subject to regulatory approval.

Ralinepag DPI Adds Further Growth PotentialBeyond the oral formulation, United Therapeutics is developing an inhaled dry-powder version of ralinepag, ralinepag DPI (RAL-DPI), in collaboration with MannKind Corporation (MNKD - Free Report) . While initially targeting PAH, management sees potential opportunities for RAL-DPI in PH-ILD, idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. At present, the candidate is in an early-stage of development. The company plans to file an investigational new drug application later this year.

UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), while AC Immune (ACIU - Free Report) carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 72% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 13.7% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.